Epizyme Stock News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients agains

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be mor

Epizyme's (EPZM) lead drug, Tazverik, is approved to treat follicular lymphoma and epithelioid sarcoma in the United States. Stiff competition in the target remains an overhang.

Epizyme's (EPZM) lead drug, Tazverik, is approved to treat follicular lymphoma and epithelioid sarcoma in the United States. Stiff competition in the target remains an overhang.

During the last session, Epizyme Inc. (NASDAQ:EPZM)’s traded shares were 1.03 million, with the beta value of the company hitting 1.06. At the end of the trading day, the stock’s price was $1.55, reflecting an intraday gain of 9.93% or $0.14. The 52-week high for the EPZM share is $9.86, that puts it down -536.13 … Will Epizyme Inc. (NASDAQ: EPZM) Stock Boom Or Bust From Here? Read More »

Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates. Nevertheless, the pipeline progress is encouraging.

Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates.

Epizyme (EPZM) delivered earnings and revenue surprises of -19.51% and 50.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Epizyme's (EPZM) CEO Grant Bogle on Q4 2021 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine, Inc. (NASDAQ: EDIT) sai

Epizyme press release (EPZM): Q4 GAAP EPS of -$0.49 misses by $0.08.Revenue of $11.6M (+38.1% Y/Y) misses by $8.82M.Revised 2022 Financial Guidance: 2022 total non-GAAP…

Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer a